Cabrero M, Lopez-Corral L, Jarque I, de la Cruz-Vicente F, et al. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial. Bone Marrow Transplant 2024 Jan 2. doi: 10.1038/s41409-023-02171.
PMID: 38167647